Novo Nordisk A/S (NYSE: NVO) has benefited from exceptional positive changes in investment behavior: positive upside/downside volume developed, and the stock’s recent price rise disrupted its longer term downtrend.
Recent notable positive changes in fundamentals have benefitted Novo Nordisk A/S (NYSE: NVO): the consensus estimate for December, 2025 increased significantly, and significant quarterly sales acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, NVO is expected to continue to be a major Value Builder.
Novo Nordisk A/S has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Novo Nordisk A/S has a neutral Appreciation Score of 45 but a very high Power Rating of 90, triggering the Positive Value Trend Rating.
Recent Price Action
On 6/28/24, Novo Nordisk A/S (NYSE: NVO) stock declined modestly by -1.2%, closing at $142.74. However, below average trading volume at 74% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 1.2% during the last week.
Be the first to comment